Clinical Trial Update: Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study of combining nivolumab with rituximab as first-line therapy for follicular lymphoma (grades 1-3A), currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• OPDIVO (nivolumab)
• Rituxan (rituximab)

Snippet

Sponsor: Dr. Eliza Hawkes | Conditions: Follicular Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING